EGFR and colorectal carcinoma: Considering two lines of evidence showing that: (1) EGFR is required for CRC progression and treatment response [28–30], and that (2) EGFR is the direct upstream regulator of RAS-GTPase and potentially mediates RAS effector signaling rebound that has been observed upon MRTX1133 treatment (Fig. 1), we thus focused on EGFR and further elucidated its role in endowing the effectiveness of KRASG12D inhibitor therapy.